SummaryRMgm-96
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 18761621 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 2.34 |
Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | A. Ecker; R.E. Sinden |
Name Group/Department | Division of Cell and Molecular Biology |
Name Institute | Imperial College |
City | London |
Country | United Kingdom |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-96 |
Principal name | ∆psop7 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Normal production of ookinetes. Reduced ookinete invasion and traversal of the midgut wall (see also 'Additional remarks phenotype'). |
Oocyst | Strong reduction of oocyst formation (0% of wild type). Only two oocysts were observed in a total of 130 mosquitoes. |
Sporozoite | No sporozoites are produced. No tramission to C57BL/6 mice by mosquito bite. When ookinetes were injected directly into the mosquito hemocoel to bypass the midgut barrier mosquito infectivity was rescued as assayed by the quantification of salivary gland sporozoites. The development of oocysts in the hemocoel is thus not affected. The formed sporozoites were also fully infectious to mice by mosquito-bite. |
Liver stage | When ookinetes were injected directly into the mosquito hemocoel to bypass the midgut barrier mosquito infectivity was rescued as assayed by the quantification of salivary gland sporozoites. The development of oocysts in the hemocoel is thus not affected. The formed sporozoites were also fully infectious to mice by mosquito-bite. |
Additional remarks phenotype | Mutant/mutation A mutant has been genereated with a C-terminal c-myc tag of PSOP7 (RMgm-112). IFA-analysis using c-myc antibodies showed an apical location in the ookinetes. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1353400 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1340000 | ||||||||||||||||||||||||
Gene product | secreted ookinete protein, putative | ||||||||||||||||||||||||
Gene product: Alternative name | PSOP7; putative secreted ookinete protein 7 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |